CompletedPhase 3NCT00554502
Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy
Studying IgA Nephropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- RWTH Aachen University
- Principal Investigator
- Juergen Floege, Prof. Dr.Medical Clinic II, University Hospital Aachen
- Intervention
- supportive therapy with: ACE-inhibitor / ARB / Statin(drug)
- Enrollment
- 148 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2008 – 2015
Study locations (30)
- Medical Clinic II, University Hospital Aachen, Aachen, Germany
- 2. Medizinische Klinik, Nephrologie, Klinikum Augsburg, Augsburg, Germany
- Campus Charité Mitte, Medizinische Klinik - Schwerpunkt Nephrologie, Centrum 13, Berlin, Germany
- Charité Campus Virchow-Klinikum, Medizinische Klinik / Nephrologie, Berlin, Germany
- Helios-Klinikum Berlin-Buch, Nephrologie Charité CCB, Berlin, Germany
- St. Joseph Krankenhaus Medizinische Klinik II, Berlin, Germany
- Klinikum Bremen-Mitte, Medizinische Klinik III, Bremen, Germany
- Uniklinik Köln, Klinik IV für Innere Medizin, Nephrologie und Allgemeine Innere Medizin, Cologne, Germany
- Universitätsklinikum Dresden, Medizinische Klinik III, Bereich Nephrologie, Dresden, Germany
- Universitätsklinikum Düsseldorf, Klinik für Nephrologie, Düsseldorf, Germany
- Universitätsklinikum Erlangen, Medizinische Klinik IV, Erlangen, Germany
- Universitätsklinikum Essen, Klinik für Nieren- und Hochdruckkrankheiten, Essen, Germany
- Universitätsklinikum Freiburg, Innere Medizin IV, Freiburg im Breisgau, Germany
- Universitätsklinikum Gießen und Marburg GmbH, Medizinische Klinik und Poliklinik II, Giessen, Germany
- Universitätsklinikum Göttingen, Zentrum Innere Medizin, Abteilung für Nephrologie und Rheumatologie, Göttingen, Germany
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00554502 on ClinicalTrials.govOther trials for IgA Nephropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07571746A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney DiseaseAstraZeneca
- RECRUITINGPHASE2NCT07146906A Study to Assess the Effects of Zigakibart on IgA Nephropathy.Novartis Pharmaceuticals
- RECRUITINGPHASE3NCT07390123Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANHaisco Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07375758A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.Beijing Mabworks Biotech Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07182227PS-002 for the Treatment of IgA Nephropathy in AdultsPurespring Therapeutics Limited
- RECRUITINGPHASE3NCT06994845Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANNovartis Pharmaceuticals
- RECRUITINGPHASE2NCT07305974A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA NephropathyRigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
- RECRUITINGPHASE4NCT07030894Nefecon and Ambrisentan in IgA NephropathyThe First Hospital of Jilin University